Multivariate analysis of DFS probability in the 450 patients with malignant disease
| . | Multivariate analysis . | ||
|---|---|---|---|
| RR . | (95% CI) . | P . | |
| Donor age | |||
| Younger than 20 y vs 20 y or older | 1.23 | (0.79 -1.90) | NS |
| Disease phase | |||
| Advanced vs early | 0.57 | (0.42 -0.78) | .0004 |
| Donor | |||
| HLA-identical family vs other donors | 1.52 | (0.95 -2.43) | .08 |
| GVHD prophylaxis | |||
| Cs-A + MTX + ALG or mAb vs other prophylaxis | .97 | (0.58 -1.64) | NS |
| cGVHD | |||
| Present vs absent | 2.04 | (1.43 -2.91) | .0001 |
| . | Multivariate analysis . | ||
|---|---|---|---|
| RR . | (95% CI) . | P . | |
| Donor age | |||
| Younger than 20 y vs 20 y or older | 1.23 | (0.79 -1.90) | NS |
| Disease phase | |||
| Advanced vs early | 0.57 | (0.42 -0.78) | .0004 |
| Donor | |||
| HLA-identical family vs other donors | 1.52 | (0.95 -2.43) | .08 |
| GVHD prophylaxis | |||
| Cs-A + MTX + ALG or mAb vs other prophylaxis | .97 | (0.58 -1.64) | NS |
| cGVHD | |||
| Present vs absent | 2.04 | (1.43 -2.91) | .0001 |
Variables with P < .1 in univariate analysis were included in the multivariate analysis.